<DOC>
	<DOCNO>NCT01101698</DOCNO>
	<brief_summary>Vessel calcification recognise cardiovascular morbidity risk factor patient chronic kidney disease ( CKD ) . Recent report indicate significant role Matrix Gla-protein ( MGP ) decrease calcification process . MGP excretion protein whose mechanism action yet fully explain activated require phosphorylation carboxylation cofactor vitamin K. These observation indicate shortage vitamin K significant risk factor development vessel calcification . Another calcification risk factor CKD patient calcium-phosphate disturbance insufficiency vitamin D3 physiological concentration stimulates MGP transcription . The aim study estimation influence vitamin K2 administration period 9 month vessel calcification 3.- 5. stage CKD patient . It prospective , randomise double-blind study carry parallel group . 60 patient CKD ( GFR 15-60 ml/min ) calcium score &gt; 10 ( Agatston score system ) qualify study . On basis randomise selection , patient divide two group : 30 patient give 90 μg vitamin K2 + 10 μg cholecalciferol 30 patient give 10 μg cholecalciferol . After 9-month treatment image diagnostic carry order estimate degree vessel calcification .</brief_summary>
	<brief_title>Vitamin K2 Vessel Calcification Chronic Kidney Disease Patients</brief_title>
	<detailed_description>Vessel calcification recognise cardiovascular morbidity risk factor patient chronic kidney disease ( CKD ) . Recent report indicate significant role Matrix Gla-protein ( MGP ) decrease calcification process . MGP excretion protein whose mechanism action yet fully explain activated require phosphorylation carboxylation cofactor vitamin K. Immunohistochemical test show high level un-carboxylated MGP calcify vessel . These observation indicate shortage vitamin K significant risk factor development vessel calcification . On hand CKD patient often display shortage vitamin . Another calcification risk factor CKD patient calcium-phosphate disturbance insufficiency vitamin D3 physiological concentration stimulates MGP transcription . Cranenburg et al . show decrease vessel calcification dialysis patient treat vitamin K2 . Vitamin K2 exist two form K1 K2 , however K2 form display calcification decrease property . There currently similar study patient chronic kidney disease require renal replacement therapy . The aim study . The aim study estimation influence vitamin K2 administration period 9 month vessel calcification 3.- 5. stage CKD patient . Materials method . It prospective , randomise double-blind study carry parallel group . 60 patient CKD ( GFR 15-60 ml/min ) whose renal replacement therapy commence earlier 9 month plan qualify study . After familiarize patient aim study obtain write consent , non-invasive test carry order estimate presence degree vessel calcification : common carotid artery intima medium thickness ( CCA-IMT ) ultrasound examination , coronary artery calcium score ( CACS ) multiscan CT well presence calcify heart valve ultrasound examination . Patients calcium score &gt; 10 ( Agatston score system ) qualify study . On basis randomise selection , patient divide two group : 30 patient give 90 μg vitamin K2+10 μg cholecalciferol ( Vitamin D ) 30 patient give 10 μg cholecalciferol . After 9-month treatment image diagnostic carry order estimate degree vessel calcification . Patients basic laboratory test evaluate study period nephrologists monthly basis . First , commencement study , 3 , 6 finally 9 month last visit , 10 ml serum plasma take frozen order conduct special marking test : phosphorylated MGP ( pMGP ) , uncarboxylated MGP ( ucMGP ) , 25-OH cholecalciferol , hsCRP . Scheduling Study Visits : Visit 0 Screening Period 1. Review inclusion exclusion criterion 2 . Obtain informed consent 3 . Obtain weight height 4 . Obtain CACS , CCA-IMT 5 . Obtain heart ultrasonography 6. Review concomitant therapy Visit 1 - Randomization 1. Review inclusion exclusion criterion 2 . Medical history concomitant disorder ( hypertension , heart ischemic disease , diabetes mellitus ) 3 . Collect blood serum chemistry ( creatinine , albumin , intact PTH , calcium , phosphor , uric acid , lipid , glucose , kaolin-kephalin time , prothrombin index blood morphology . 4 . Collect blood pMGP , ucMGP , 25-OH cholecalciferol , hsCRP 5. Review concomitant therapy 6 . Randomization : 90 μg vitamin K2+10μg cholecalciferol 10μg cholecalciferol ( Vitamin D ) 9 month Visit 2,4,5,7,8 Visits every month 1 . Complete physical examination 2 . GFR obtain 3 . Drug dispension Visit 3,6 9 month : 1 . Complete physical examination 2 . GFR obtain 3 . Collect blood serum chemistry ( creatinine , albumin , intact PTH , calcium , phosphor , uric acid , lipid , glucose , kaolin-kephalin time , prothrombin index blood morphology . 4 . Collect blood pMGP , ucMGP , 25-OH cholecalciferol , hsCRP 5 . Obtain CACS , CCA-IMT 6 . Obtain heart ultrasonography 7. Review concomitant therapy</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Vitamin MK 7</mesh_term>
	<criteria>1 . Subject chronic kidney disease ( creatinine clearance 1560 ml/min/1,73m2 CockroftGault formula ) 2 . Patient life without dialysis therapy 9 month 3 . Subject 3070 year age 4 . Calcium score &gt; 10 ( per Agatston score system ) 1 . Atherosclerosis generalisata ( myocardial infarction treat PTCA Percutaneous Transluminal Coronary Angioplasty CABG Coronary Artery Bypass Graft , symptomatic heart insufficiency , cerebrovascular accident ) 2 . Subject history cardiac abnormality , include symptomatic asymptomatic arrhythmia ( atrial fibrillation ) 3 . Patient cardiac pacemaker 4 . Subject require longterm use vitamin K antagonist</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Vitamin K</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>coronary artery calcification</keyword>
	<keyword>intima medium thickness</keyword>
</DOC>